The Evaluation of effectiveness of heparin nebulizer in reduction of respiratory distress in patients with COVID-19

Phase 2

Conditions: COVID-19.
COVID-19, virus identified
U07.1

Registration Number: IRCT20210513051275N1

Lead Sponsor: Islamic Azad University

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 60

Inclusion Criteria

All patients with COVID-19 treated in Yazd In the Summer of 2021, which was proven by radiographic involvement in radiography andThey have respiratory distress and O2 SAT below 90%.

Exclusion Criteria

Patients treated with anticoagulants
Patients with a variety of coagulation disorders
Patients who have impaired coagulation tests at initial evaluation.
Patients with proven cardiovascular disease
Patients taking medications that interfere with the medications we use.
Patients with severe COVID-19 who require ICU admission and mechanical ventilation prior to intervention.
Patients who do not have clear lung involvement on radiography and respiratory distress.

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber of breaths. Timepoint: Before the intervention and three days after the start of the intervention. Method of measurement: Cardiac device for monitoring and recording information in a questionnaire.;Percentage of arterial blood oxygen saturation (SpO2). Timepoint: Before the intervention and three days after the start of the intervention. Method of measurement: Pulse oximetry of cardiac monitoring device and recording information in a questionnaire.;Patient body temperature. Timepoint: Before the intervention and three days after the start of the intervention. Method of measurement: Digital thermometer (forehead temperature measurement).;Severity of lung involvement. Timepoint: Before the intervention and three days after the start of the intervention. Method of measurement: Radiographic device.;Severe shortness of breath. Timepoint: Before the intervention and three days after the start of the intervention. Method of measurement: Patient self-declaration.

Secondary Outcome Measures